Nitazoxanide

Nitazoxanide is the parent member of a class of drugs called the thiazolides, chemically a nitrothiazolyl-salicylamide derivative ^[1][2]. It was originally introduced as an antiprotozoal medicine, and its defining feature is an unusually wide spectrum of activity that spans single-celled parasites, worms, certain anaerobic bacteria, and many viruses ^[1].

In approved clinical use, nitazoxanide treats infectious diarrhea caused by the intestinal protozoa Cryptosporidium parvum and Giardia lamblia in immunocompetent patients ^[1]. Beyond these labelled indications, it has demonstrated activity against a broader set of protozoa and helminths, including Entamoeba histolytica and various intestinal worms, which has made it a versatile antiparasitic option in regions where such infections are common ^[1].

The drug's second life has been as a repurposed antiviral. Investigators identified it as a first-in-class broad-spectrum antiviral agent and studied it for influenza, where a clinical trial found that it shortened the duration of symptoms and reduced viral shedding compared with placebo ^[2]. In cell-culture and clinical work it has shown activity against a striking variety of RNA and DNA viruses, including respiratory syncytial virus, rotavirus and norovirus, hepatitis B and hepatitis C, and several coronaviruses ^[2][3]. During outbreaks of emerging coronaviruses it was highlighted as a candidate against Middle East respiratory syndrome coronavirus, in part because it inhibits viral protein expression and tempers inflammatory cytokine production ^[4].

Pharmacologically, nitazoxanide itself is short-lived after absorption because it is rapidly deacetylated to tizoxanide, a metabolite that is highly bound to plasma proteins and carries much of the drug's activity ^[1]. It is supplied as oral tablets and as an oral suspension for children, and an extended-release formulation was studied for chronic hepatitis C ^[2]. In the United States it is a prescription medicine that has also become available in generic form.

A notable practical point is its tolerability. Across trials the rate of side effects has generally been similar to placebo, and extensive post-marketing experience in tens of millions of adults and children supports a favorable safety profile, which has encouraged its continued study for new indications ^[2].

Nitazoxanide is a prescription antiparasitic that is generally well tolerated over its short three-day course. The most common side effects are mild: stomach pain, diarrhea, nausea, and headache. A harmless quirk is that it can turn urine a bright yellow-green, and it may tint the eyes slightly; this fades after the course ends. It is taken with food, which improves absorption. There are few significant drug interactions, though it is highly protein-bound so caution is used with other tightly bound drugs; safety in early pregnancy is not fully established.

Nitazoxanide has a narrow interaction profile, and almost all of it comes from one property: its active metabolite tizoxanide is more than 99.9% bound to plasma protein. That leaves it competing for albumin binding sites with other highly bound drugs, and where the displaced drug has a narrow therapeutic index the free concentration can rise sharply.

Warfarin is the worked example. In human plasma in vitro, tizoxanide increased the free fraction of warfarin by roughly 20 to 34 fold across a range of concentrations, which in practice means a higher INR and more bleeding risk than the warfarin dose alone would predict. Phenytoin and other tightly bound narrow index drugs raise the same concern, though the evidence there is theoretical rather than measured.

Beyond protein binding there is little to report. Nitazoxanide does not meaningfully inhibit the major cytochrome P450 enzymes in vitro, so the usual CYP3A4 and CYP2D6 questions largely do not arise. Absorption roughly doubles when it is taken with food, which is a formulation matter rather than a drug interaction.

Checking a whole stack? Run it through interactions + stacks.

Nitazoxanide was first synthesized in the mid-1970s by the French-trained researcher Jean-Francois Rossignol, working with Raymond Cavier at the Pasteur Institute in Paris, where it was initially investigated as a veterinary anthelmintic against tapeworms. Rossignol went on to champion its development for human medicine, founding Romark Laboratories to carry the compound through clinical study.

The United States Food and Drug Administration approved nitazoxanide under the brand name Alinia in 2002 for diarrhea caused by the protozoa Cryptosporidium parvum and Giardia lamblia, first in children and subsequently in adults. Over the following two decades attention shifted toward its unexpectedly broad antiviral properties, and the thiazolides came to be described as a first-in-class, host-directed antiviral platform. On this basis the drug has been studied against influenza, hepatitis B and C, rotavirus, and, during the pandemic, SARS-CoV-2.

Nitazoxanide enjoys a reputation as an unusually well-tolerated and versatile medicine. In its approved niche, clearing stubborn Cryptosporidium and Giardia infections, it is valued for a clean safety record that permits use even in young children. Its broader appeal comes from a remarkable breadth of antiviral activity in the laboratory, spanning influenza, coronaviruses, hepatitis viruses, and rotavirus, which has fueled sustained interest in repurposing it for respiratory and emerging viral infections. That enthusiasm is tempered by honesty; clinical results in viral disease have been mixed, and several large trials, including studies conducted during the COVID-19 pandemic, did not consistently translate its test-tube promise into decisive patient benefit. Even so, its safety, oral convenience, and novel host-directed mechanism keep it a compelling and much-studied compound.